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ABSTRACT Next-generation DNA sequencing (NGS) has progressed enormously over the past decade, transforming genomic
analysis and opening upmany new opportunities for applications in clinical microbiology laboratories. The impact of NGS on
microbiology has been revolutionary, with newmicrobial genomic sequences being generated daily, leading to the development
of large databases of genomes and gene sequences. The ability to analyze microbial communities without culturing organisms
has created the ever-growing field of metagenomics andmicrobiome analysis and has generated significant new insights into the
relation between host andmicrobe. The medical literature contains many examples of how this new technology can be used for
infectious disease diagnostics and pathogen analysis. The implementation of NGS in medical practice has been a slow process
due to various challenges such as clinical trials, lack of applicable regulatory guidelines, and the adaptation of the technology to
the clinical environment. In April 2015, the American Academy of Microbiology (AAM) convened a colloquium to begin to de-
fine these issues, and in this document, we present some of the concepts that were generated from these discussions.
Use of next-generation DNA sequencing (NGS) (Table 1) ininfectious disease diagnostics has progressed slowly over the
past 10 years despite continued advances in sequencing technol-
ogy. The first commercial NGS platform, the GS20 sequencer
from 454 Life Sciences, which was originally released in 2005 (1,
2), resulted in a more than 100-fold increase in the amount of
microbial genomic sequence data produced in a day compared to
preceding instruments. Despite the growing body of literature and
research broadly applying sequencing-based technology to disease
pathophysiology, epidemiology, and clinical diagnostics, the clin-
icalmicrobiology laboratory has yet towidely adoptNGS technol-
ogy. As microbiology laboratories are faced with a wealth of inno-
vative and often costly molecular technologies, the role of NGS in
clinical infectious disease diagnostics needs to be carefully evalu-
ated.
A number of highly publicized case reports and clinical studies
have showcased the application of NGS as a single diagnostic tool
with the potential to be broadly applicable to infectious disease
diagnostics. Metagenomic (Table 1) sequencing has demon-
strated its ability to identifymicrobial pathogenswhere traditional
diagnostics have otherwise failed. For example, it is estimated that
63%of encephalitis cases go undiagnosed despite extensive testing
(3). Several cases in the literature have successfully employedNGS
to diagnose rare, novel, or atypical infectious etiologies for en-
cephalitis, including cases of infection by Leptospira (4), astrovirus
(5), and bornavirus (6). In one case, 38 different diagnostic tests
had been conducted and failed to yield an actionable answer be-
fore a single NGS assay was performed, which identified the
pathogen (4). Similarly, the utilization of metagenomic NGS
identified divergent astrovirus clades in a pair of patients with
encephalitis and demonstrated the unusual zoonotic potential of a
group of these viruses (7).
Another promising application of NGS technology is hospital
infection control surveillance programs and community outbreak
investigations (8). By conducting whole-genome sequencing
(WGS) (Table 1), organisms can be identified at the subspecies/
strain level based on the single nucleotide polymorphisms (SNPs)
(Table 1) and other variants (Table 1) in their genotype. WGS
through NGS technology offers greater precision than do more-
traditional typing tools such as multilocus sequence typing and
pulsed-field gel electrophoresis, which may assist in refining out-
break investigations and better guide infection control interven-
tions (9). Because WGS analysis requires significant amounts of
sequencing data, traditional sequencingmethods preclude the use
of WGS analysis for outbreak investigations. However, NGS plat-
forms can generate the large volume of data needed for SNP or
variant analysis and have led to a rapid expansion in the use of
WGS for public health investigations. For example, WGS using
NGS technology was applied to investigate an outbreak of
hemolytic-uremic syndrome caused by an unusual strain of Esch-
erichia coli in Germany (10), the origins of the 2010HaitianVibrio
cholerae epidemic (11), a series of methicillin-resistant Staphylo-
coccus aureus infections in a neonatal intensive care unit (12), and
the origins of a series of nosocomial carbapenem-resistant Kleb-
siella pneumoniae infections (13), among many others.
While identification of causative microorganisms of disease is
the chief responsibility of clinical microbiology laboratories, con-
ducting antimicrobial resistance testing to guide therapy is among
themost important tests conducted in the laboratory.NGShas the
potential to suggest antimicrobial resistance through identifica-
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TABLE 1 Glossary of terms used in DNA sequence analysis
Term Abbreviation Definition
16S rRNA gene A slowly evolving gene in bacteria whose sequence
is used for definition of taxa. It is a gene that is
targeted for sequencing in microbiome analysis,
where the goal is enumeration of the taxa
present in a community.
Alignment The process of comparing the sequence of a single
sequencing read or a contig/whole genome
following assembly to a reference genome.
The goal is often to identify the organism
from which a sequencing read came or to
identify variants within the sequence.
Assembly Reconstructing a genome, in whole or in part,
from the fragment sequences produced
by WGS (or mWGS).
Contig A contiguous stretch of sequence produced when
a series of overlapping sequence reads are
merged to produce a single longer sequence.
Dideoxynucleotide sequencing A “classical” method of DNA sequencing that preceded
NGS and is frequently called Sanger sequencing.
Metagenomics Analyzing a mixture of microbial genomes, a metagenome,
without separating the genomes or culturing the organisms.
Metagenomic whole-genome
shotgun sequencing
mWGS The application of WGS to a metagenomics sample. DNA
is extracted from the sample, producing a
mixture of genomes, which are then subjected
to WGS en masse.
Microbiome A community of microbes comprising bacteria, viruses,
and fungi and other eukaryotic microbes. Often
the target of metagenomic analyses.
Next-generation sequencing NGS A collection of DNA sequencing methods that each
use different biochemical approaches and instruments
to produce data in vastly larger amounts, at greatly
lower cost, in shorter time, and with less manual
intervention than previous methods.
Reference genome A genome sequence of a particular organism that can
be used as a standard, e.g., for alignment or
comparison of other genomes.
Read The basic element produced by DNA sequencing.
Sequencing of a DNA fragment produces a
series of bases called a sequencing read.
Sanger sequencing A “classical” method of DNA sequencing that preceded
NGS but was almost exclusively used from the
1970s until the advent of NGS. Compared to
NGS, it produced fewer data, was more
expensive, and required more manual work.
Single nucleotide polymorphism SNP A difference of a single base compared to a reference
genome. These can be substitutions of one
base for another or insertion/deletion
of a base (indel).
Variant Any difference in a DNA sequence compared to
a reference sequence. This can be a single-base
difference (SNP) or insertions, deletions,
inversions, or translocations of larger
stretches of sequence (structural variants).
Whole-genome shotgun sequencing WGS Randomly fragmenting an entire genome and obtaining
DNA sequence from the fragments to produce
a collection of random DNA sequences. This
can be applied to a single bacterium or to a
mixture (metagenomc; see mWGS). These
data can be used to identify variants following
alignment of genes by comparison to sequence
databases or to compare genome structures
following assembly.
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tion of known resistance genes (14). AlthoughWGS is in the early
stages of development, studies have suggested that WGS can be
used to predict antibiotic resistance with performance character-
istics approaching those of traditional phenotypic testing. Stoesser
et al. (15) demonstrated sensitivity and specificity of 96% and
97%, respectively, when using WGS to predict antibiotic resis-
tance for clinical isolates of E. coli and K. pneumoniae. Compara-
tive genomic sequencing has also been used to identify daptomy-
cin resistance due to point mutations in metabolic genes that
occurred during therapy for two cases of vancomycin-resistant
enterococcal bacteremia which were ultimately fatal (16, 17). Ear-
lier application of WGS might have detected these point muta-
tions and guided therapy. However, it has not been established if
WGS can be broadly applied to the full spectrum of pathogenic
bacteria, particularly those with a diverse armamentarium of re-
sistance mechanisms. WGS analysis of antimicrobial resistance
genes could be particularly beneficial for slow-growing or
difficult-to-culture organisms and organisms that elude pheno-
typic testing altogether. The use of WGS is not limited to the
detection of bacterial resistance genes. WGS has also been applied
for the following purposes: detection of low-level drug resistance
among human immunodeficiency virus (HIV) “escape” variant
populations (e.g., protease inhibitor [PI] and reverse transcriptase
minor sequence variants) and coreceptor tropism (CCR5 and
CXCR4) and analyses that are not possible using current geno-
typic and phenotypic HIV assays (18). These successes and poten-
tial applications of WGS analysis have been made possible by the
advance of NGS technology, which provides the tools to produce
useful WGS data.
Metagenomic shotgun sequencing (mWGS) (Table 1) is often
used to studymicrobial communities in humandisease in order to
identify correlative or causative relations. Such communities
comprise hundreds of different taxa of bacteria, viruses, and fungi
and other eukaryotic microbes. Many of these organisms are dif-
ficult to culture, and culture-independentmethods of performing
comprehensive sampling of these complex communities have
been the major obstacle to analysis. NGS is currently the best
available analytical approach to profile microbiomes (Table 1) for
this purpose. To date, NGS has helped elucidate the role of the
lung and gut microbiomes in both general health and various
diseases, including obesity, inflammatory bowel disease, cystic fi-
brosis (CF), metabolic syndrome, type II diabetes, and cardiovas-
cular disease (19–23). AsNGS continues to expandour knowledge
base on metagenomics, microbiome analysis may produce diag-
nostic or prognostic biomarkers to guide therapeutic decisions.
There is a long-standing precedent in clinical microbiology
laboratories to adopt new technology that complements or sup-
plants existing “gold standard” testing. The viral culture bench is
all but extinct in most clinical laboratories, with PCR-based mo-
lecular assays currently dominating viral diagnostics. Nonviral
microbial diagnostics have been relatively slow to adoptmolecular
technology, but this is rapidly changing with a new generation of
molecular diagnostics that utilize specific PCR primers for differ-
ent bacterial, parasitic, and fungal targets. Several of these multi-
plex assays have already receivedU.S. Food andDrug Administra-
tion (FDA) clearance and offer laboratories an attractive and easy
way to detect clinically relevant microbial pathogens. Similarly to
the impact of PCR technology, microbial NGS diagnostics offer
another step forward in the quality and quantity of information
that could potentially be provided to clinicians and patients. In
April 2015, the American Academy of Microbiology (AAM) con-
ducted a colloquium to critically evaluate the trends in the use of
NGS for infectious disease diagnostics. Below,we describe someof
the concepts that evolved from the AAM’s NGS colloquium (re-
port to be published).
NEXT-GENERATION SEQUENCING
DNA sequencing technology was previously dominated by proce-
dures using the dideoxynucleotide chain termination method
(also referred to as Sanger sequencing) (Table 1) for close to
30 years. In the mid-2000s, a number of new methods began to
appear, commonly referred to as the “next-generation sequencing
methods.” The first method that was widely commercialized was
the “pyrosequencing” method—a method that formed the basis
for the 454 Life Sciences instruments for about 10 years until the
company closed in 2015. These instruments had a major impact
on microbial genomics and became the leading platform for pro-
ducing whole-genome sequences from individual bacteria as well
as the platformof choice for sequencing 16S rRNA (Table 1) genes
in microbiome analyses.
Since the advent of NGS, there has been an ongoing expansion
of sequencing methods and instruments as well as continual im-
provements in the quality, quantity, and cost of sequences that are
produced. The spectrum of common and available instruments
current as of July 2015 is shown in Table 2, which indicates the
considerable range in characteristics of NGS options.
An understanding of how these characteristics match the var-
ious NGS applications is useful to appreciate the strengths or lim-
itations of different sequencing approaches. To sequence a single
microbial genome, the genome is fragmented into manageable-
size pieces, which are then used inWGS (Fig. 1).Depending on the
sequencing platform, this can produce sequences (i.e., reads) (Ta-
ble 1) that range from hundreds of bases to thousands or tens of
thousands of bases in length. When the goal is to produce a mi-
crobial genome, the reads are assembled into a single genome
sequence using a variety of computational strategies. Often, the
assembly (Table 1) leaves gaps, and the individual chunks of
genomic sequence that result are called contigs (Table 1). When
identifying variants in the genome (e.g., for typing or tracking),
the reads are directly aligned with a reference genome (Table 1)
where the sequence variants are determined. The smaller the
length of sequence read, the more contigs and gaps that are pro-
duced during the assembly process. Hence, there is a preference
for longer sequence reads. To obtain a complete sequence without
gaps, one often uses both short and long reads to combine the
strengths of these various sequencing approaches (24). However,
the platforms producing shorter reads are often less expensive and
can yield large amounts of data. Moreover, the accuracy of base
calls comprising the sequence read is also important. The lower
the accuracy of the read, the more reads (i.e., coverage) that are
required to obtain good contigs, ultimately driving up the se-
quencing costs. In addition, when reads have errors, it is harder to
identify the true sequence variants. At present, platforms that pro-
duce longer reads tend to have lower accuracy and users have to
consider the tradeoffs between the various platforms when de-
signing a project.
Another major application for NGS is metagenomic sequenc-
ing. In this case, one starts with a particular specimen type such as
stool, saliva, a nasal swab, etc., with the goal of determining the
bacteria, viruses, fungi, and other microbes that are present. Fol-
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lowing DNA extraction, a series of processing and bioinformatics
steps are performed to produce NGS data for analysis (Fig. 2),
analogous to the whole-genome sequence of an individual mi-
crobe described above; however, in this case themethod is applied
to a mixture/community of microbes. While the genomic se-
quences produced can be assembled, because of the various abun-
dances of organisms, there is often not enough sequence from
rarer organisms to produce a complete genome, and assembly
results in very short contigs for these genomes in the mixture.
More commonly, the sequence reads are aligned against databases
of many (typically thousands) genome sequences to identify the
likely source organism for the sequence. The abundance of such
source organisms is estimated from the number of reads that
match their genomes. In this way, one can identify and estimate
the abundance of organisms that are present in the original patient
sample.
The high throughput of NGS allows data to be produced from
many individual bacteria/samples in a single sequencing run of
hours to days. This is a vast improvement over the early days of
bacterial sequencing when a single bacterial genome project could
take years. Likewise, because a metagenomic sample is complex
and contains hundreds of taxa at abundances ranging over many
orders of magnitude, previously it was not possible to accurately
assess the community structure by culture-based methods or tra-
ditional Sanger sequencing, which could handle only cultivable
organisms or hundreds of sequences at best. With the availability
of NGS, it is now possible to obtainmillions or more of sequences
per run, thus enabling deep sampling and more descriptive anal-
ysis of the microbial community on a truly useful level.
CLINICAL APPLICATIONS
The potential clinical applications of NGS are vast and engage
clinical microbiology at every level of the development process,
such as outbreak tracking across the country, hospital infection
control surveillance, pathogen discovery, mutation detection in a
specific isolate, identification of multiple pathogens in a single
sample, identification of viral quasispecies, and individual host
response to infection (Fig. 3). These tests are poised to revolution-
ize infectious disease diagnostics and the practice of clinical mi-
crobiology. Initial reports of NGS applications for clinical diag-
nostics first appeared more than 5 years ago; however, the
technology has not yet entered routine use within clinical micro-
TABLE 2 Current spectrum of popular, available NGS instruments (as of July 2015)a
Instrument
Read length
(accuracy)
No. of
reads/run Run time Run cost ($)
No. of genomes/
metagenomes per run Comment
ILMNMiSeq 300 bases
(high up to
250 bases)
20 million 2.5 days 1,500 40/4 Read pairs
ILMN NextSeq 150 bases (high) 400 million 1.2 days 5,000 400/60 Read pairs
ILMN
HiSeq 2500
250 bases (high) 300 million 2.5 days 8,000 300/80 Read pairs,
rapid run mode
PB RSII ~10 kb (low
for single pass)
70,000 4 h 1,200 3/TBD Shorter (e.g., 2-kb)
reads have higher
quality; no
paired ends
LT Ion PGM 400 bases 5 million 7 h 750 7/1 PGM318 chip;
no paired ends
LT Ion Proton 200 bases 80 million 4 h 1,000 30/16 PI chip; no
paired ends
ONT MinION 10 kb–100 kb (low) Variable Variable 1,000 TBD No paired ends;
beta testing
a Abbreviations: ILMN, Illumina; LT, Life Technologies; PB, Pacific Biosciences; ONT, Oxford Nanopore Technologies. TBD, to be determined. ILMN is from Illumina. LT is from
http://allseq.com/knowledgebank/sequencing-platforms/life-technologies-ion-torrent. Genomes/run, 100 coverage of a 3-Mb genome. Metagenomes/run, 5 million reads
(pairs)/metagenome.
FIG 1 NGS genome analysis. The general process of using NGS for analysis of
a single genome is depicted in this figure. Note that there are many variations
on this approach. Purified DNA (i.e., input genome) is fragmented and run
through the DNA sequencing process. The sequencing instrument produces
either short (e.g., for Illumina) or long (e.g., for Pacific Biosciences) sequence
reads depending on the platformused.When the goal is to produce a complete
genome (e.g., for identifying virulence or antibiotic resistance genes or for
comparative genomic studies), the reads are assembled into genomes using
specialized software. Some gaps in the assembly may occur, leading to a draft
genome sequence composed of many contigs. When the genome is assembled
without gaps, it is said to be closed. When the goal is to identify variants (e.g.,
SNPs) with respect to a reference genome, the reads can be aligned directly
with the reference genome and sequence variants can be identified using spe-
cialized programs. These variants serve to define the organism at the subspe-
cies and strain level and are useful in epidemiological tracking as well as to
identify mutations that occur.
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biology laboratories. Reports continue to appear in the medical
literature of individual case studies or small-scale applications of
NGS to clinical microbiology, but experience remains limited.
The technology itself is still hobbled by the enormous amount of
basic research and resources needed to transform this technology
into a robust clinical application for infectious disease diagnostics.
To date, the medical community is still awaiting large-scale clini-
cal trials to establish the utility ofNGS in different clinical settings;
however, comprehensive funding and incentives for these studies
are limited.
Although NGS has the potential to provide a huge volume of
information to health care practitioners with respect to both mi-
crobial characteristics and the host response to disease, it will be
necessary to determine strategies to pragmatically deal with this
data barrage. Many of the potential applications to clinical medi-
cine are not known. In the field of bacteriology, NGS has particu-
lar limitations in determining which organisms are merely “inno-
cent bystanders” or are colonizers rather than active pathogens.
For instance, a potentially pathogenic microorganism identified
from one specimen type, such as cerebrospinal fluid (CSF) or
synovial fluids, which are typically thought to be sterile, may be
normal in the skin, gut, or mouth.
The potential implications for physicians/practitioners, and
particularly antimicrobial stewardship, are staggering. One im-
portant question: if currently a certain percentage of practitioners
treat patients with antibiotics even when lacking evidence of a
bacterial pathogen, what will they do when presented with a
pathogen that is likely (but not absolutely) a contaminant?
More importantly, a paradigm shift in the understanding of
molecular diagnostics will be necessary for clinicians and profes-
sionals in the clinical microbiology community. Both molecular
diagnostics and traditional culture-based technology have their
strengths and weaknesses. One of the strengths of NGS assays is
the ability to detect many microorganisms directly from a patient
sample without needing additional testing or a priori knowledge
of the type of pathogen. NGS can potentially detect viruses, bac-
teria, yeast, fungi, and parasites without the need for additional
individual testing. However, both traditional technologies and
NGS assays have limitations in detection that can be clearly de-
fined. But while culture absolutely indicates the presence of living
organisms, the presence of organismal DNA is less definitive.
Ultimately, clinical studies and eventually clinical trials exam-
ining patient outcomes will be necessary to reinforce the cost sav-
ings and benefit of usingNGS-based clinical tests for the diagnosis
of infectious disease. A prominent issue with such studies is the
scarcity of funding. Because of how expensive these analyses are to
conduct, they can be unattractive to industry and require a certain
amount of patience and determination from the clinical commu-
nity to perform correctly and in an economically wise manner.
Moreover, such studies require establishing fundamentals such as
standard operating procedures for NGS diagnostics. At present,
there is no standardization between studies, much less between
different institutions. All aspects of the NGS diagnostic pipeline
remain variable, including clinical specimen collection, sequenc-
ing parameters, data analysis/interpretation, and data reporting.
Such details must be established before clinical outcomes can be
systematically examined.
Determining the optimal approach to advance the use of NGS
FIG 2 NGSworkflow. A high-level overview of the steps taken in theNGS data production process and some of the equipment and software used in this process.
The specific instruments and programs may vary as there are multiple solutions (e.g., Table 2). DB, database; QA, quality assurance; seq’ing, sequencing; conc,
concentration; LIMS, laboratory information management system.
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poses serious challenges. For example, how would a clinical labo-
ratory determine the analytical validation of a device that could
potentially pick up any known or novel pathogens? While the
majority of clinical infections are typically attributed to a finite
number of bacterial, viral, and fungal pathogens, amain attraction
of NGS for clinical diagnosis is the ability to capture rare or un-
suspected, yet potentially actionable, pathogens. It is tremen-
dously appealing to identify both pathogen and patient genomic
sequence information for everything from virulence genes to
strain-level sequence variants to an assessment of the patient re-
sponse to infection or effectiveness of antibiotic therapy. The ad-
vancement of NGS technology into pathogen genomics could po-
tentially provide supplemental descriptive or predictive
information regarding the potential antimicrobial resistance gene
profile of themicroorganism and allow formore rapid selection of
appropriate antimicrobial therapy. Although early studies have
reported promising results for antimicrobial resistance detection,
the most valuable piece of antimicrobial resistance information is
the antimicrobials to which the organism is susceptible (15, 25),
and it is unclear what the strength of NGS for predicting suscep-
tibility as opposed to resistance will be. Additionally, as bacteria
and viruses are constantly evolving new resistance mechanisms,
reference databases would have to be continuously updated to
include novel resistance genes and mutations in order for NGS to
be an effective predictor. Thus, it seems unlikely that the clinical
laboratory will be moving away from phenotypic confirmation in
the near future. Additional clinical studies are needed to explore
the capabilities of NGS assays for these applications and the po-
tential partnership between NGS and culture-based assays.
As NGS technology continues to mature, the research and
medical communities will need to establish the analytical perfor-
mance of each assay, the clinical validity for different pathogens,
and, most importantly, the clinical niche for NGS. The shift to
molecular diagnostics will require a change in the thinking of cli-
nicians and clinical microbiology professionals. Upcoming gener-
ations of physicians, clinical providers, and clinical microbiolo-
gists will need to adjust to the strengths and limitations of these
new tools. Like any new powerful technology, molecular diagnos-
tics pose challenges in data interpretation and reporting but could
more quickly and completely diagnose infection and provide crit-
ical information for clinical management. Despite all of the po-
tential limitations and hurdles to the clinical applications of NGS
assays, they present a remarkable opportunity to advance the field
of clinical microbiology.
REGULATORY CONSIDERATIONS
The imminent adaptation of NGS-based infectious disease diag-
nostics in the clinical microbiology laboratory poses significant
regulatory challenges for U.S. device developers and manufactur-
ers. The technology itself is still evolving, and there is a need for
new development of guidelines and streamlining of insurance re-
imbursement codes for the use of NGS testing in clinical microbi-
ology laboratories. While the test is going through the approval
process, an upgrade or new instrument will likely appear on the
market that can perform that same test with a shorter turnaround
time and at a lower cost. However, constant technology improve-
ment is not unique to clinical microbial NGS. This is one of the
current obstacles where resources are scarce to develop validated
tests while demand for this novel technology is rising. As men-
tioned in the introduction, various publications showcase situa-
tions in which microbial NGS-based tests guided or improved
diagnostic and therapeutic decisions. Such decisions cannot be
made with current laboratory diagnostic devices.
Infectious disease NGS-based diagnostic devices are in vitro
diagnostic (IVD) tests intended for use in the diagnosis of diseases
or other conditions, including infections. Some tests are used in
laboratory or other health professional settings, and other tests are
intended for use by a patient to collect samples at home. IVDs are
medical devices as defined in section 210(h) of the U.S. Federal
Food, Drug, and Cosmetic Act and may also be biological prod-
ucts subject to section 351 of the Public Health Service Act. Sim-
ilarly to other medical devices, IVDs are subject to premarket and
postmarket controls. IVDs are also subject to the Clinical Labora-
tory Improvement Amendment of 1988 (CLIA ‘88) (26). In the
United States, clinical diagnostic tests have to make an appropri-
ate premarket submission and obtain approval or clearance for
their test from the FDA prior to marketing. Sequence-based clin-
ical diagnostic devices for the microbiology laboratory are raising
new policy and regulatory issues; thoughts presented here are pre-
liminary and do not represent finalized FDA policy. The FDA
encourages submitters to contact the FDA, using the presubmis-
sion program to discuss the premarket submission strategy for
their specific test (27).
During FDA’sMicrobial Sequencing workshop held on 1 April
2014, scientific and clinical community leaders emphasized the
benefits of regulatory oversight of infectious disease NGS-based
FIG 3 Potential clinical applications formetagenomics sequencing. There are
numerous potential applications of NGS technology to the clinical microbiol-
ogy laboratory. Each entry in the chart represents a potential area for the
utilization of NGS diagnostics and/or future research.
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diagnostic devices due to challenges that these devices pose for
patient management (28). The following challenges were identi-
fied at the workshop: (i) the absolute need for immediate and
actionable results, (ii) the broad range of specimen types (e.g.,
urine, blood, CSF, stool, sputum, and others), (iii) the broad di-
versity of the infectious disease agents possibly present within a
single specimen, and (iv) the dynamic nature of infectious disease
agents. The request from scientific and clinical community leaders
for guidance on infectious disease sequencing parallels the chal-
lenges faced by matrix-assisted laser desorption ionization
(MALDI)–time of flight (TOF) mass spectrometry diagnostics
prior to their widespread integration into the clinical microbiol-
ogy laboratory.
Moreover, the publications referenced in the introduction and
input from stakeholders at FDA’s Microbial Sequencing work-
shop outlined that detection and identification of infectious dis-
ease organisms and antimicrobial resistance or virulence markers
have progressed from culture-based methods to molecular meth-
ods using nucleic acid amplification and hybridization technolo-
gies. Today, single-approach high-throughput techniques or NGS
may potentially replace previous methods which required several
different tests. An infectious disease NGS diagnostic device differs
from traditional devices that target specific organisms or viru-
lence/resistance markers by being able to simultaneously detect
every organism present in a sample during a single run. These
challenges call for a novel regulatory approach tailored to the spe-
cific NGS technology and microbiology application used in the
diagnostic assay. To date, the only in vitro diagnostic NGS system
(i.e., assay and instrument) to have obtained FDA marketing au-
thorization is the Illumina MiSeqDx system. This authorization
marks a significant milestone for NGS technology (29). The Illu-
minaMiSeqDx system is tailored for the detection of cystic fibrosis
(CF) (i.e., cystic fibrosis carrier screening for the general popula-
tion and detection of the CF gene for CF patients); the Illumina
MiSeqDx system has not been cleared by the FDA for microbial
diagnostic use. Currently, the FDA is developing concepts for val-
idation of NGS tests for infectious disease diagnostics and the
detection of antimicrobial resistance and virulence markers. The
FDA is also working on introducingmodels for streamlining clin-
ical trials for the validation of infectious disease NGS diagnostic
tests and other sequence-based microbial molecular diagnostics.
Quality metrics and metadata parameters for microbial genomic
sequence entries are currently being developed for use in regula-
tory decisions.
Since policy and regulatory issues for these devices are still
evolving, the FDA presubmission process is a helpful tool for de-
velopers to inquire about specific information on studies required
for evaluation of NGS-based devices. These studies are aimed at
elucidating how NGS technologies can aid in infectious disease
diagnostics and at gaining a better understanding of potential
NGS clinical implementation strategies. The purpose of the pre-
submission program is to give a submitter an opportunity to dis-
cuss specific questions with the FDA regarding product develop-
ment or application preparation. The FDA review of
presubmission protocols leads to better-prepared submissions.
Through the presubmission process, input can be given on possi-
ble approaches to validation studies and data for the evaluation of
infectious disease NGS-based diagnostics (Fig. 4). The FDA can
FIG 4 The FDA is considering the following information for the clearance/approval of an infectious disease NGS-based test/assay. The FDA presubmission
process can be utilized for outstanding questions and to request additional information while policy is still being developed (26). IRB, institutional review board.
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provide guidance on the available regulatory pathways and assis-
tance on how to evaluate performance using sequence outputs
from infectious disease NGS-based devices. Quality metrics for
reference databases are among the most critical validation issues
as discussed by stakeholders during the FDA Microbial Sequenc-
ing workshop. Efforts toward generating an initial set of high-
quality, regulatory-grade microbial genomic reference sequences
through the FDA-ARGOS project in collaboration with various
federal agencies are under way. The FDA’s vision is a public, high-
quality, regulatory-grade microbial reference database that con-
tains qualified sequence data for use by developers and clinical end
users.
As with other molecular biology-based diagnostic devices,
FDA is considering using a “one-system” approach for the evalu-
ation of infectious disease NGS diagnostic devices—from sample
collection through the output of clinically actionable data. The
components of the system generally include a specimen collection
device, instruments, reagents, software (if applicable) used to gen-
erate the sequencing library or otherwise prepare the specimen for
sequencing, the sequencing instruments along with the associated
reagents and data collection elements that generate the raw se-
quence reads, and the data analysis pipeline (i.e., assembly, anno-
tation, and variant calling, as applicable). Further, the FDA is con-
sidering using methods from the discipline of systems science to
evaluate these devices. This approach will evaluate, in parallel, the
“system” as a whole, from specimen collection to the individual
steps in the sequencing data pipeline to the generation of clinically
actionable data.
FDA-ARGOS. The FDA, in collaboration with various federal
agencies, has developed the database entitled FDA-ARGOS (FDA
database for regulatory-grade microbial sequences; BioProject
231221). To promote a least-burdensome regulatory approach for
devices that incorporate infectious disease NGS diagnostic tech-
nology, the FDA considers the use of an alternative comparator
method for clinical evaluation that relies heavily on public data-
bases populated with regulatory-grade target genomic reference
sequences. This database supplies a set of validated regulatory-
grademicrobial genomic sequence entries which is available at the
National Center for Biotechnology Information (NCBI) website.
Regulatory-grade microbial sequences are near-complete high-
quality draft genomes with metadata requirements (30).
In order to advance from proof of concept to implementation
of NGS-based diagnostics in U.S. clinical laboratories and hospi-
tals, assays must undergo standardization, optimization, valida-
tion, and, eventually, automation. Once each step of the workflow
has been optimized for efficiency, overall functionality and per-
formance characteristics must be determined for the entire test.
Validation requires the calculation of analytical sensitivity and
specificity, accuracy, precision, and limit of detection (31). The
National Institute for Standards and Technology (NIST) is devel-
oping whole-genome microbial reference standards to support
the validation process for genomic sequencing-based diagnostic
assays (32). Four microbial species that are clinically significant
and vary in genome characteristics (e.g., size, GC content, and
presence of accessory elements) are being characterized by NIST
through evaluating genome assembly, base-level analysis,
genomic purity, and genomic stability (33). These reference ma-
terials can be used during appropriate steps to support validation
of a microbial NGS-based diagnostic assay. NGS is a multistep
technology for which validation has to occur among all levels of
“wet” and “dry” processes described above. Guidance for devel-
oping specific protocols and quality control procedures that assess
NGS tests is needed. For example, metrics should be established
for the number of individual sequence reads that must match a
genomic reference sequence or marker for a particular organism
(32, 34). To aid in validating the bioinformatics or “dry” compo-
nents of NGS, attendees at the AAM’s colloquium suggested an in
silico, characterized data set that could be downloaded and run
through the clinical laboratory’s bioinformatic pipeline. It may
be necessary for a group of regulatory agencies such as the FDA,
the Centers for Medicare and Medicaid Services (CMS), the
National Institutes of Health (NIH), the Centers for Disease
Control and Prevention (CDC), and the College of American
Pathologists (CAP) to collaborate on the formulation of guide-
lines for the validation of infectious disease NGS-based diag-
nostic assays.
Another regulatory challenge that encompasses the transition
of NGS into the clinical microbiology laboratory is management
of patient data. Because microbial NGS data are generated from a
patient’s clinical sample, storage of the genomic informationmust
be secure and uphold Health Insurance Portability and Account-
ability Act (HIPAA) regulations. Offsite remote cloud processing
and data storage have become a popular alternative to local bioin-
formatics infrastructure, although no regulatory legislation is in
place for these online tasks. It is well known that an established
bioinformatics workflow, including storage and retrieval facilities
for microbial genome sequence analyses, requires a substantial
financial investment which may not be available or feasible for
many clinicalmicrobiology laboratories. Raw sequence reads con-
sume considerable storage space, and thus, it was suggested at the
colloquium to deposit rawdata in the Short ReadArchive (SRA) at
the NCBI and the assembled/annotated genome in a central re-
pository (35). It was also highly recommended by colloquium
attendees to document only the clinically actionable result and
analysis parameters in the patient’s medical record, thereby de-
creasing the data footprint cost.
Not only do microbial genomic data hold immense value for
the clinical microbiology field, but their power could be leveraged
to help the public health and scientific research communities
through implementation of open data sharing practices. Many
discussions at the AAM’s colloquium focused on the need for a
publicly available, unified, genomic reference database that is fil-
teredwithmetadata andmaintains patient confidentiality andpri-
vacy laws. A centralized database with a continuous stream of new
microbial genomes could serve as a vital resource (35, 36). It was
suggested that guidelines for responsible data sharing and transfer
be created by a group of relevant stakeholders to assist in maxi-
mizing public availability of microbial genomic data and to limit
the creation of private genome sequence databases. Incorporation
of new data repositories could occur with established databases
such as the multiorganizational effort known as the International
Nucleotide Sequence Database Collaboration (INSDC), an initia-
tive that endorses data sharing among three existing databases:
NCBI, EuropeanNucleotide Archive (ENA), andDNAData Bank
of Japan (DDBJ). To truly understand the benefits that NGS diag-
nostic assays could have for the broader clinical microbiology
community, data sharing through a constantly evolving, central-
ized reference repository is essential.
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CONCLUSION
Despite the enormously attractive potential of NGS for infectious
disease diagnosis, there are many challenging, time-consuming,
and costly bridges to cross before this technology can become
mainstream and part of the clinical standard of care. However, the
clinical literature has demonstrated that this technology can be
successfully applied to solve medical diagnostic dilemmas and be
likely useful for clinical cases that fail or challenge the limits of
traditional laboratory testing. Although many potential impedi-
ments to the utilization of NGS-based diagnostics exist, it would
be a loss to themedical community if this technology could not be
applied to patient care in some capacity. The burden is on the
infectious disease and genomics communities to bring these tools
to the world of clinical diagnostics and to keep pace with the on-
going evolution of the analytical and computational aspects of
NGS. Ten years ago, it would have been inconceivable that a single
human genome could be sequenced in a day and for less than
$1,000. Yet, today the clinical microbiology laboratory is facing
the same scenario, and one cannot fully envision all other infec-
tious disease applications that will be possible in the near future.
The rapid evolution of NGS challenges both the regulatory frame-
work and the development of laboratory standards and will re-
quire additional funding and incentives to drive tangible improve-
ments and progress. Cooperation among themedical and research
communities, industry, regulatory bodies, and professional soci-
eties will help to develop innovative solutions to these challenges
and to realize the potential benefit that NGS has for patients and
their families.
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